Data Sheet (Cat.No.T0025)

TargetMol

Haloperidol

Chemical Properties



CAS No. : 52-86-8

Formula: C21H23ClFNO2

Molecular Weight: 375.86

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson's disease.
Targets(IC50)	5-HT Receptor,Dopamine Receptor

Solubility Information

Solubility	Ethanol: 8 mg/mL (21.28 mM),Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 45.45 mg/mL (120.92 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.55 mg/mL (12.11 mM),Suspension. 10% DMSO+90% Saline: < 4.55 mg/mL (12.11 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6606 mL	13.3028 mL	26.6057 mL
5 mM	0.5321 mL	2.6606 mL	5.3211 mL
10 mM	0.2661 mL	1.3303 mL	2.6606 mL
50 mM	0.0532 mL	0.2661 mL	0.5321 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cai G, et al. Mol Pharmacol. 1999 Nov;56(5):989-96.
Wesołowska A, Rychtyk J, Gdula-Argasińska J, et al Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats. Neuropsychiatric Disease and Treatment. 2021, 17: 2105.
Partyka A, Górecka K, Gdula-Argasińska J, et al.Selective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats.Pharmaceuticals.2023, 16(2): 154.